HBM Healthcare Investments has signed a binding agreement to sell a majority stake in Swixx Biopharma to SK Capital for €1.5 billion while retaining a significant minority and keeping a 25.1% stake in Swixx Healthcare (spun off in 2024); founders and other shareholders including Mérieux Equity Partners will likewise sell a majority of their holdings. The deal prompted a revaluation that raises HBM’s NAV by about CHF13.50 per share (≈5% uplift); closing is expected in H1 2026 and cash proceeds should exceed the investment’s book value as of Sept. 30. HBM’s total cash outlay was €26m (with €10.5m already returned) and the investment has generated roughly CHF300m of value (>10x the original), supporting a material liquidity and value realization for shareholders; HBM shares closed up 2.11% at CHF217.50.
HBM Healthcare Investments announced a binding agreement to sell a majority stake in Swixx Biopharma to SK Capital Partners for €1.5 billion while retaining a significant minority interest and maintaining a 25.1% stake in Swixx Healthcare (spun off in 2024). The company, together with founders and other shareholders including Mérieux Equity Partners, will sell a majority of their holdings; the exact percentage sold by HBM in Swixx Biopharma was not quantified in the release. HBM revalued its Swixx Biopharma holding, recording an NAV uplift of ~CHF13.50 per share (about +5%), and expects cash proceeds on close (targeted H1 2026) to exceed the investment's book value as of September 30. The original investment was €26 million with €10.5 million already returned; the position has generated roughly CHF300 million of added value to date (over tenfold the original outlay), and HBM shares rose 2.11% to CHF217.50 on the announcement, reflecting positive market reception.
The transaction materially crystallizes value for HBM and validates its private-market sourcing and value-creation track record, while retained minority exposure preserves upside participation in Swixx’s future growth. Execution risk remains given the unquantified majority stake sale, the mid-2026 closing timeline and the potential for final proceeds or adjustments at closing to differ from current revaluation assumptions. For portfolio-level implications, the deal should improve HBM’s near-term liquidity and reported NAV, reduce concentration risk from a legacy private investment and transform a private unrealized gain into monetized proceeds available for redeployment.
Investors should monitor subsequent disclosures detailing the precise percentage sold, final cash consideration and timing to confirm the NAV uplift and realized gain assumptions, consider partially realizing gains or rebalancing if they want to lock the reported uplift given the pending 2026 close, and retain some exposure or watch HBM's statements on how proceeds will be redeployed since the company keeps a meaningful minority stake and may pursue new private-market investments.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
